Freedom Investment Management Inc. Has $826,000 Stock Position in Danaher Corporation $DHR

Key Points

• Freedom Investment Management Inc. reduced its holdings in Danaher Corporation by 35.9%, owning 4,027 shares after selling 2,255 shares, with a total value of approximately $826,000.
• Several institutional investors made significant changes to their positions in Danaher, with GHP Investment Advisors increasing their stake by 396.0% during the same period.
• Danaher recently received favorable ratings from analysts, including a shift from "hold" to "buy" by Wall Street Zen and a price target increase by Barclays to $225.00.

Freedom Investment Management Inc. lowered its position in Danaher Corporation (NYSE:DHR - Free Report) by 35.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,027 shares of the conglomerate's stock after selling 2,255 shares during the period. Freedom Investment Management Inc.'s holdings in Danaher were worth $826,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. FAS Wealth Partners Inc. increased its holdings in Danaher by 20.6% during the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock worth $2,203,000 after purchasing an additional 1,639 shares in the last quarter. MGO One Seven LLC increased its holdings in Danaher by 485.7% during the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock worth $5,145,000 after purchasing an additional 20,813 shares in the last quarter. Asahi Life Asset Management CO. LTD. bought a new position in Danaher during the 1st quarter worth about $539,000. Horizon Financial Services LLC increased its holdings in Danaher by 20,400.0% during the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock worth $1,681,000 after purchasing an additional 8,160 shares in the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc raised its holdings in shares of Danaher by 6.1% in the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 34,763 shares of the conglomerate's stock valued at $7,126,000 after purchasing an additional 2,009 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Stock Performance

Shares of DHR traded up $0.80 during trading hours on Friday, hitting $206.09. The company had a trading volume of 1,979,809 shares, compared to its average volume of 3,319,294. The firm has a market cap of $147.57 billion, a price-to-earnings ratio of 43.85, a PEG ratio of 2.87 and a beta of 0.73. The business has a fifty day moving average of $201.65 and a 200-day moving average of $199.49. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.90. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same period in the prior year, the firm earned $1.72 earnings per share. The company's revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 11.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

DHR has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft decreased their price objective on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. UBS Group lowered their price target on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Robert W. Baird boosted their price target on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research report on Friday, July 18th. Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Finally, Barclays reiterated an "overweight" rating and issued a $225.00 target price (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $247.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.